Marksans Pharma share price

High risk
  • 52%Low risk
  • 52%Moderate risk
  • 52%Balanced risk
  • 52%High risk
  • 52%Extreme risk
  • ₹215.65(0.65%)
    April 23, 2025 15:29:58 PM IST
    • NSE
    • BSE
  • Vol : 933.95K (NSE + BSE)
    Last 20 day avg : 1.69 M

Marksans Pharma is trading 0.65% upper at Rs 215.65 as compared to its last closing price. Marksans Pharma has been trading in the price range of 219.00 & 212.05. Marksans Pharma has given -27.82% in this year & 10.29% in the last 5 days. Marksans Pharma has TTM P/E ratio 36.48 as compared to the sector P/E of 28.79.There are 2 analysts who have initiated coverage on Marksans Pharma. There are 1 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 104.56 Crores in its last quarter.Listed peers of Marksans Pharma include Alivus Life Sciences (0.35%), Granules India (0.82%), Marksans Pharma (0.65%).The Mutual Fund holding in Marksans Pharma was at 3.15% in 31 Dec 2024. The MF holding has increased from the last quarter. The FII holding in Marksans Pharma was at 21.95% in 31 Dec 2024. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Key Metrics

Updated on Apr 23, 2025, 10:26 PM UTC

  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.28
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    4.70
    Higher than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    26.33
    Higher than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    4.18
    Indicates overvaluation
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    1.38
    High volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.12
    Higher than industry
Price range
Day Range
Lowest
212.05
Highest
219.00
52 week range
Lowest
130.15
Highest
358.50
Marksans Pharma News
Marksans Pharma Financials
Financials
Financials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
View all
  • Income
  • Balance Sheet
  • Cash Flow
Loading...
Units in the chart are in crores
Insights
  • Financial
  • Valuation
    • financial-insightsCompany is profitable
    • financial-insightsThe company's revenue grew in December quarter by 16.33% from Rs 681.85 crore to Rs 586.13 crore, year-on-year
    • financial-insightsThe company has grown its December quarter profit by 25.62% from Rs 83.24 crore to Rs 104.56 crore, year-on-year
    • financial-insightsThe debt to equity of the company is higher than the industry median
    • financial-insightsCompany can comfortably pay off its interest obligations with its earnings
Marksans Pharma Technical Analysis
Pivot Level - classic
Info
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
  • R1
  • 256.48
  • R2
  • 290.62
  • R3
  • 334.83
Pivot212.27
  • S1
  • 178.13
  • S2
  • 133.92
  • S3
  • 99.78
Short Term
Info
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Info
Considers price movement over the last 6 months
Not Available
  • Very Bearish
  • Bearish
  • Neutral
  • Very Bullish
  • Bullish
Trends unavailable at the moment.
Marksans Pharma Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Alivus Life Sciences
Neutral
1,026.900.3512,612.7126.415.332.220.63
Granules India
Neutral
484.450.8211,815.7528.593.610.314.72
Marksans Pharma
Neutral
215.650.659,763.2629.784.70.289.20
Procter & Gamble Health
Moderately Bearish
5,239.601.458,682.6339.8116.112.681.28
Fdc
Neutral
435.450.947,106.0823.433.34-0.60
Marksans Pharma Shareholding
View All
Shareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
    No Data
    Shareholding pattern for Marksans Pharma is currently unavailable
    Please check back later.
    Shareholding Insights
    • InsightsPromoter(s) holding is moderate at 43.87%
    • InsightsPromoter(s) have increased the stake in the company in last 12 months
    • InsightsFIIs are invested in this company
    • InsightsFIIs holding has increased by 0.64 percentage points from previous quarter
    • InsightsMutual Funds holding has increased by 0.13 percentage points from previous quarter
    Mutual Fund Ownership
    View all
    Old Bridge Focused Equity Fund Regular Growth
    NA
    • Amount Invested (Cr.) 41.32
    • % of AUM 3.11
    Kotak Special Opportunities Fund Regular Growth
    NA
    • Amount Invested (Cr.) 56.24
    • % of AUM 2.92
    Kotak MNC Fund Regular Growth
    NA
    • Amount Invested (Cr.) 44.50
    • % of AUM 2.13
    UTI Healthcare Fund Regular Plan Growth
    NA
    • Amount Invested (Cr.) 15.31
    • % of AUM 1.47
    UTI Small Cap Fund Regular Growth
    2/5
    • Amount Invested (Cr.) 57.56
    • % of AUM 1.39
    Marksans Pharma Corporate Actions
    View all
    • Board Meetings
    • AGM
    • Dividends
    • Bonus
    • Split
    • Rights
    Meeting DatePurpose
    2025-02-11Quarterly Results
    2024-11-12Quarterly Results
    2024-08-13Quarterly Results
    2024-05-30Audited Results & Final Dividend
    2024-02-13Quarterly Results
    About the company Marksans Pharma
    • IndustryBiotechnology & Drugs
    • ISININE750C01026
    • BSE Code524404
    • NSE CodeMARKSANS
    Marksans Pharma Limited is an India-based company, which is engaged in research, manufacturing and marketing of generic pharmaceutical formulations in the global markets. The Company's product portfolio spreads various therapeutic segments of cardiovascular system (CVS), central nervous system (CNS), antidiabetic, pain management, cough and cold, gastroenterological, and anti-allergies. Its product portfolio includes tablets (plain, enteric-coated and film-coated), hard capsules, soft gelatin capsules, oral liquids and ointments. Its consumer self-care products (over the counter) include pain management, upper respiratory, digestive health, vitamins minerals and supplements (VMS) and skin care products. The Company's prescription - Rx therapeutic segments include CVS, CNS, oncology, anti-diabetics and anti-biotic. Its end consumers include retail chains, pharmacy stores, hospitals and institutions. It has manufacturing facilities in India, the United Kingdom and the United States.
    • Management Info
    • Mark SaldanhaExecutive Chairman of the Board, Managing Director
    • Jitendra SharmaGroup Chief Financial Officer
    • Harshavardhan PanigrahiCompany Secretary, Compliance Officer
    • Sathish KumarManaging Director - UK Operations
    • David MohammedManaging Director - Australia Operations
    • Varddhman JainWhole Time Director
    • Sandra SaldanhaWhole Time Director
    • Anjani KumarChief Operating Officer - US Operations
    Marksans Pharma Share Price FAQs

    Marksans Pharma is trading at 215.65 as on Wed Apr 23 2025 09:59:58. This is 0.65% upper as compared to its previous closing price of 214.25.

    The market capitalization of Marksans Pharma is 9763.26 Cr as on Wed Apr 23 2025 09:59:58.

    The average broker rating on Marksans Pharma is Strong Buy. The breakup of analyst rating is given below -

    • 1 analysts have given a strong buy rating
    • 1 analysts have given a buy rating
    • 0.00 analysts have given a hold rating
    • 0.00 analysts have given a sell rating
    • 0.00 analysts have given a strong sell rating

    The 52 wk high for Marksans Pharma is 358.50 whereas the 52 wk low is 130.15

    Marksans Pharma can be analyzed on the following key metrics -

    • TTM P/E: 36.48
    • Sector P/E: 28.79
    • Dividend Yield: 0.28%
    • D/E ratio: -

    Marksans Pharma reported a net profit of 313.70 Cr in 2024.

    The Mutual Fund Shareholding was 3.15% at the end of 31 Dec 2024.

    Quick Links
    EQUITY QUICK LINKS
    Marksans Pharma QUICK LINKS
    FROM MARKETS
    RELATED LINKS
    Quarterly Results
    Business News/Market/Market Stats/   Marksans Pharma share price

    Wait for it…

    Log in to our website to save your bookmarks. It'll just take a moment.